泽璟制药 (688266)

Suzhou Zelgen Biopharmaceuticals Co., Ltd.

KSH

Tags

ImmunotherapyInnovative DrugsPharmaceutical ManufacturingPharmaceuticals and HealthcareFund Reduction PositionsFund Heavy PositionsForeign Capital BackgroundBiological ProductsHundred-Yuan StocksSTAR Market 100 IndexSTAR Market Biotechnology IndexTechnology Growth LayerMargin Trading and Securities LendingHigh Price-to-Book RatioChemical Pharmaceuticals医药生物

K-Line Chart

No K-line data available

Company NameSuzhou Zelgen Biopharmaceuticals Co., Ltd.
Listing Date2020-01-23
Issue Price33.76RMB
Registered Capital26470.818610k RMB
Legal RepresentativeZELIN SHENG
Registered AddressNo. 209, Chenfeng Road, Yushan Town, Kunshan City, Jiangsu Province
IndustryChemical Pharmaceuticals
Main BusinessThe issuer is an innovation-driven chemical and biological new drug R&D enterprise focused on multiple therapeutic areas including oncology, bleeding and blood diseases, and hepatobiliary diseases.
Company ProfileSuzhou Zelgen Biopharmaceuticals Co., Ltd. (referred to as Zelgen) was founded in 2009 and is located in the Kunshan National High-Tech Zone, Jiangsu Province. It is a Sino-foreign joint venture established by management and technical teams from the Chinese and American pharmaceutical industries. The company has four subsidiaries: US-based Gensun Biopharma, Shanghai Zelgen Pharmaceutical Technology Co., Ltd., Suzhou Zelgen Biotechnology Co., Ltd., and Zelgen Holdings. Zelgen is dedicated to the independent R&D, production, and sales of innovative drugs. The company's goal is to become a leading enterprise in new drug R&D in China for areas such as oncology, bleeding and blood diseases, and hepatobiliary diseases. Its market strategy is global-facing with a focus on China, aiming to develop and produce innovative drugs with independent intellectual property rights that are safe, effective, and affordable for patients, thereby meeting the substantial domestic and international pharmaceutical market demand.

Stock Details

1. Key Indicators

  • Total Shares(W): 26470.82
  • Circulating A-Shares(W): 26470.82
  • Earnings Per Share(RMB): -0.3500
  • Net Assets Per Share(RMB): 4.3407
  • Operating Revenue(W RMB): 59344.01
  • Total Profit(W RMB): -9831.96
  • **Net Profit Attributable to Parent(W RMB) **: -9341.62
  • Net Profit Growth Rate(%): 4.58
  • Weighted Return on Equity(%): -7.7800
  • Operating Cash Flow Per Share(RMB): -0.0630
  • Undistributed Profit Per Share(RMB): -8.3494
  • Capital Reserve Per Share(RMB): 11.7468

2. Main Business

The main business covers:

  • Innovative drug development and manufacturing in multiple therapeutic areas including oncology, bleeding and blood diseases, and immune-inflammatory diseases

3. Company Basic Information

  • Company Name: ZEJI Pharmaceutical
  • Listing Date: Unknown
  • Industry: Unknown
  • Address: Unknown
  • Website: Unknown
  • Company Profile: Unknown

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
Data not available - - - -

5. Concept Sectors

  • Concept sectors information not available

Remarks

  • Data update date: 2025-09-30
  • Data source: Public market information